Skip to main content
OpenTrials
Completed

NCT Number: NCT04168970

Percutaneous Left Stellate Ganglion Block In Out-of-hospital Cardiac Arrest Due to Refractory VEntricular Arrhythmias (LIVE Study)

This is an observational, prospective study to verify the feasibility and practicability of percutaneous stellate ganglion block (PSGB) in patient suffering from a refractory out-of-hospital cardiac arrest (OHCA) due to a shockable rhythm and the eventual occurrence of complication related to it. The study will also assess the rate of ventricular fibrillation termination and the return of spontaneous circulation (ROSC) until admission and transfer of care to the receiving hospital is higher in the patients treated with PSGB as compared to historical controls.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Fondazione IRCCS Policlinico San Matteo, Pavia, PV, Italy

Loading trial locations.

About this study

All patients meeting the inclusion/exclusion eligibility criteria will be consecutively enrolled in the study. The decision to perform PSGB or not and the type of technique (anatomic or echo-guided) is left to the EMS rescue team medical doctor (MD), according to clinical practice (standard of care).

The Emergency Medical System (EMS) rescue team medical doctor (MD) will be asked to perform PSGB after all the actions provided in the ACLS algorithm and which are considered useful in the clinical situation (intubation and ventilation, administration of iv/io adrenaline, amiodarone or lidocaine, use of mechanical chest compression, etc.). Considering that the PGSB is useful for the treatment of refractory Ventricular Arrhythmias, the PGSB will be performed after the administration of the 4th shock, if the 3rd shock was unsuccessful in restoring a stable perfusing rhythm, considering all the shocks administered both by an AED or by manual defibrillator. The evaluation of the effectiveness of the 3rd shock will be carried out at the end of the two-minute cycle after shock delivery, as recommended by the Guidelines. If the MD will arrive on the scene after the delivery of the 3rd shock, the PSGB should be executed as soon as possible after performing all the actions which are considered useful in the clinical situation. The MD, based on his confidence, can choose to use the anatomic technique or the echo-guided PSGB technique. The technique will be performed in the pre-hospital setting. Those patients with refractory OHCA transported with ongoing ACLS who receive the fourth shock once in the Emergency Department will be also considered. On the contrary, the patients with pre-Hospital ROSC who suffer a new cardiac arrest once in the Emergency Department won't be considered in the present study. The MD will be asked to evaluate also the presence of anisocoria immediately before the PSGB and 1-2 minutes after the PSGB. In case of absence of anisocoria 2 minutes after PSGB, MD can try PSGB another time. The anaesthetic that will be used for PSGB is Lidocaine 2% (10cc bolus), which is already available among EMS drugs. Considering the setting and the need of a rapid effect of the anaesthetic, it is expected that the anaesthetic used will be lidocaine 2%, which is also already available among EMS drugs.

After the end of the event, the MD will be asked to fill in a Questionnaire regarding the feasibility of the technique in the pre-hospital setting, the practicability of its implementation compared to the usual procedures performed in the pre-hospital setting and any problems/complications encountered. The responses will be scored from 1 to 10 (1=no feasibility; 10=perfect feasibility). All eventual complications associated with PSGB will be carefully recorded.

The effectiveness of the PSGB will be evaluated if at least one shock will be delivered after the execution of PSGB.

The data will be compared to our historical cohort of patients with the same OHCA characteristics (first shockable rhythm and who received more than 4 shocks) enrolled in the Out-of-Hospital Cardiac Arrest Registry "Lombardia CARe" in the Province of Pavia (Italy).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients with an OHCA, occurred in the Province of Pavia, in which the first rhythm was a shockable one and in which the cause of the cardiac arrest is medical (following Utstein-style 2014).
  • Patients who received L-PSGB after at least 4 unsuccessful shocks during ACLS algorithm;

Exclusion criteria

  • Patients in which the cause of the cardiac arrest is non-medical following Utstein-style 2014 (trauma, overdose, drowning, electrocution, asphyxia, etc.)
  • Patients who has an anisocoria at the arrival of medical doctor on the scene.
  • Patients whose neck is judge unsuitable for PSGB by the operator (i.e. presence of big scar, thyroid goiter, etc.)

Treatment and study plan

PSGB

Procedure

Percutaneous stellate ganglion block: injection of 10 mL of local anaesthetic (lidocaine 2%) at the C6 level using the anatomic technique or the echo-guided technique The anaesthetic that will be used for PSGB is lidocaine.

Primary outcomes

  1. Rate of ventricular fibrillation termination

    Time frame: From L-PSGB execution to 10 minutes after the L-PSGB execution

    Primary electrocardiographic outcome: we will measure the rate of VF termination after L-PSGB, namely the number of patients no longer in VF after the procedure

Secondary outcomes

  1. Rate of return of spontaneous circulation (ROSC)

    Time frame: at hospital admission (assessed within 24 hours after L-PSGB)

    To assess whether the rate of return of spontaneous circulation is higher in the patients treated with L-PSGB as compared to historical controls.

  2. Rate of return of spontaneous circulation (ROSC) if anisocoria is present

    Time frame: at hospital admission (assessed within 24 hours after L-PSGB)

    To assess whether the rate of ROSC is higher in the patients treated with L-PSGB and in which anisocoria is present after the L-PSGB, but not before L-PSGB

  3. Survived event

    Time frame: at hospital admission (assessed within 24 hours after L-PSGB)

    To assess whether the rate of ROSC until admission and transfer of care to the receiving hospital is higher in the patients treated with L-PSGB as compared to historical controls.

  4. Survived event if anisocoria present

    Time frame: at hospital admission (assessed within 24 hours after L-PSGB)

    To assess whether the rate of ROSC until admission and transfer of care to the receiving hospital is higher in the patients treated with PSGB and in which anisocoria is present after the L-PSGB, but not before L-PSGB

  5. Survival at hospital discharge

    Time frame: Up to hospital discharge (estimated within 30 days after L-PSGB)

    To assess whether the survival rate at hospital discharge is higher in the patients treated with L-PSGB.

  6. Survival at hospital discharge if anisocoria present

    Time frame: Up to hospital discharge (estimated within 30 days after L-PSGB)

    To assess whether the survival rate at hospital discharge is higher in the patients treated with PSGB and in which anisocoria is present after the L-PSGB, but not before L-PSGB

  7. Survival with good neurological outcome

    Time frame: 1 month after the cardiac arrest

    To assess whether the survival rate with good neurological outcome (CPC 1 or 2) at 1 month after the event is higher in the patients treated with L-PSGB

  8. Survival with good neurological outcome if anisocoria present

    Time frame: 1 month after the cardiac arrest

    To assess whether the survival rate with good neurological outcome (CPC 1 or 2) at 1 month after the event is higher in the patients treated with PSGB and in which anisocoria is present after the L-PSGB, but not before L-PSGB.

  9. Rate of rhythm conversion after first defibrillation

    Time frame: During resuscitation

    The rate of rhythm conversion at the first defibrillation after the L-PSGB

  10. Rate of rhythm conversion after second defibrillation

    Time frame: During resuscitation

    The rate of rhythm conversion at the second defibrillation after the L-PSGB

  11. Rate of complications

    Time frame: Up to hospital discharge (estimated within 30 days after L-PSGB)

    The occurrence of complications associated with PSGB in the pre-hospital setting

  12. Feasibility of PSGB in the pre-hospital setting

    Time frame: Up to 24 hours after the event

    The feasibility and practicability of L-PSGB in the pre-hospital setting based on a questionnaire filled out by the physician who performed the L-PSGB. Physicians who had performed L-PSGB were asked to complete a questionnaire regarding the feasibility of the technique in the prehospital setting, the practicality of its application compared with procedures routinely performed in the prehospital setting, and any complications encountered. Responses were rated on a 10-point Likert scale (1 = no feasibility; 10 = perfect feasibility).

Sponsors and collaborators

Lead sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Other

Collaborators

  • AREU - Agenzia Regionale Emergenza Urgenza
  • University of Pavia

Registry information

Official study title

Percutaneous Left Stellate Ganglion Block In Out-of-hospital Cardiac Arrest Due to Refractory VEntricular Arrhythmias (LIVE)

Acronym: LIVE

Important dates

Study start
2019
Primary completion
2025
Study completion
2026
First posted
Nov 19, 2019
Registry last updated
Aug 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.